To take advantage of this offer, click on the link at the end.
Dexcom G5 Mobile starter kit offer
Option 1: x1 transmitter, x1 sensor £160 (£90 off RRP of £251.25)
Option 2: x1 transmitter, x1 pack of 4 sensors £275 (£130 off RRP of £405)
Dexcom G5 Mobile 'Subscribe and Save' for existing users
Option 1: £160/month for x4 transmitters, x7 packs of 4 sensors, so 28 sensors over 12 months, a saving of £315 on RRP.
Option 2: £220/month for x4 transmitters, x12 packs of sensors, so 48 over 12 months, a saving of £620 RRP.
To take advantage of this offer, click HERE.
Product: G5 CGM
Screen: Receiver or smart phone
This is a stand-alone system that works
closely with some of the current insulin
pump systems, particularly Animas
pumps and the Omnipod system. With
quite a fan-base, Dexcom users claim it's
not only accurate but easier to wear than
other CGM options.
Following the decision by Johnson
& Johnson to cease to support insulin
pumps globally withdrawing its popular
Animas pump in the UK as well as
elsewhere, when it comes to choosing
their next pump at their next pump change,
Animas users may decide to move over to
a pump that also incorporates Dexcom to
keep that continuity.
With a relatively newly formed UK
company, Dexcom is starting to make
greater in-roads across the country
seeking to broaden the user base out
beyond those already on an insulin pump.
The positve impact of CGM for
diabetics on injections was shown via the
DIaMonD study (Multiple Daily Injections
and Continuous Glucose Monitoring in
Diabetes), the first-of-its-kind study that
demonstrated the impact of CGM on
HbA1c and hypoglycaemia in participants
on multiple daily injections (MDI).
Published in January 2017 in Journal
of the American Medical Association
(JAMA), the study showed Dexcom
CGM System users on MDI achieved a
1% average reduction in HbA1c after
24 weeks of regular use. In addition to
better glucose control, participants also
increased time spent in target range and
spent less time in hypo and hyperglycemia
when they used a Dexcom CGM system,
compared to those who used only a
standard meter to monitor their glucose.
There was a 49% reduction in time spent
in hypo (less than 3.9 mmol/L). The study
also dispelled certain perceptions, such
as CGM being too complicated to use, as
patients demonstrated significant HbA1c
reductions regardless of education level,
maths ability, or age. A high level of
adherence was also achieved with 93%
of patients still using the Dexcom CGM
system more than at the end of the study.